All In Biotech

Drug Trial Radar · NCT06015568

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity

Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

172

Planned (sponsor's estimate)

Start

Sep 1, 2023

Primary completion

Nov 4, 2028

Study completion Jul 4, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.

Conditions

  • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

Interventions

  • MCLA-129: 1500mg or 2000mg IV Q2WDrug

    Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs

  • Befotertinib: 75 mg or 100 mg Po QDDrug

    The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD. Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)Time frame: First 28 days of treatment
  2. Maximum Tolerable Dose (MTD)Time frame: First 28 days of treatment
  3. Treatment-Emergent Adverse Event (TEAE) in Part 1Time frame: Until 30 days after the last dosing
  4. Overall Response Rate (ORR) in Part 2Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai chest hospital

    Shanghai, China

  • The first affiliated hospital of bengbu medical college

    Bengbu, Anhui, China

  • Hunan cancer hospital

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.